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ABSTRACT Activation of caspases represents one of
the earliest biochemical indicators for apoptotic cell
death. Therefore, measurement of caspase activity is a
widely used and generally accepted method to deter-
mine apoptosis in a wide range of in vivo and in vitro
settings. Numerous publications characterize the role
of the heme-catabolizing enzyme heme oxygenase-1
(HO-1) in regulating apoptotic processes. Different
metalloporphyrins representing inducers and inhibitors
of this enzyme are often used, followed by assessment
of apoptotic cell death. In the present work, we found
that caspase-3-like activity, as well as activity of
caspase-8 measured in either Fas (CD95) ligand-treated
Jurkat T-lymphocytes or by the use of recombinant
caspase-3 or -8, was inhibited by different metallopor-
phyrins (cobalt(III) protoporphyrin IX, tin and zinc(II)
protoporphyrin-IX). Moreover, employing the mouse
model of Fas-induced liver apoptosis these properties
of porphyrins could also be demonstrated in vivo. The
metalloporphyrins were shown to inhibit caspase-3-
mediated PARP cleavage. Molecular modeling studies
demonstrated that porphyrins can occupy the active site
of caspase-3 in an energetically favorable manner and
in a binding mode similar to that of known inhibitors.
The data shown here introduce metalloporphyrins as
direct inhibitors of caspase activity. This finding points
to the need for careful employment of metalloporphy-
rins as modulators of HO-1.—Blumenthal, S. B., Ki-
emer, A. K., Tiegs, G., Seyfried, S., Ho¨ltje, M., Brandt,
B., Ho¨ltje, H.-D., Zahler, S., Vollmar, A. M. Metallopor-
phyrins inactivate caspase-3 and -8. FASEB J. 19,
1272–1279 (2005)
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The caspase family comprises at least 10 cysteine pro-
teases that play a critical role during apoptotic cell
death. Their name phrases the active cysteine group
and the characteristic cleavage of their targets at aspar-
tate residues. Caspases are expressed as inactive zymo-
gens in the cytoplasm. The pro-caspases become acti-
vated during apoptosis by proteolytic processing at
specific sites, followed by assembly of the active form
(1–3). The apoptotic caspases are generally divided
into two classes: the initiator caspases, which include
caspase-8, -9, and -10; and the effector caspases, which
include caspase-3, -6, and -7. The active enzyme can in
turn cleave a number of defined substrates involved in
the biochemical and morphological feature of apopto-
sis. One example is poly-ADP ribose polymerase
(PARP), which is cleaved at a specific Asp-Glu-Val-Asp
(DEVD) sequence. Caspase-3 has been identified as the
caspase responsible for much of this activity (4). These
findings led to the measurement of caspase-3-like activ-
ity as a reliable, simple, and generally accepted method
to quantify apoptotic cell death (5).
Heme oxygenase (HO) is the rate-limiting enzyme in
the degradation of heme (6). It catalyzes the oxidative
cleavage of heme to yield equimolar amounts of free
iron, carbon monoxide (CO), and biliverdin, which is
subsequently converted to bilirubin by biliverdin reduc-
tase. As known so far, the HO system includes three
isoforms of the enzyme. Of these, the HO-1 isoform is
distributed ubiquitously and is strongly induced by a
variety of physiological and pathophysiological stimuli,
including heme, heavy metals, endotoxins, oxidants,
and several inflammatory cytokines (7). The substrate
of HO-1, Fe protoporphyrin IX (FePP, heme, hemin),
is a multifunctional molecule in nature. The porphyrin
ring is a tetra dentate ligand that binds metals through
two imino nitrogen atoms capable of accepting protons
and two pyrrole nitrogens capable of either losing or
accepting protons. Several metals such as Fe, Cu, Zn,
Sn, and Co can form a complex with the porphyrin ring
(8). The binding pocket of HO has specificity toward
the side chains of the porphyrin ring and does not
recognize the metal moiety of the molecule. In conse-
quence, metalloporphyrins, in which the heme-iron has
been replaced by other metals like Zn, Sn, and Co, can
compete for heme and inhibit the activity of the
enzyme because they cannot be degraded to bile pig-
ments (9). On the other hand, heme and other metal-
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loporphyrins are able to induce HO-1 expression, to
various degrees though (10–12). In fact, cobalt(III)
protoporphyrin IX (CoPP) is often used as a strong
HO-1 inducer in different experimental settings be-
cause its inducing effect on HO synthesis overweighs its
inhibitory effect on the enzyme. In contrast to CoPP,
SnPP and ZnPP are only weak inducers of HO-1 expres-
sion but markedly decrease its activity, which explains
their usage as potent HO-1 inhibitors.
Several studies in the recent past have led to the
hypothesis that HO-1 confers cellular protection
against oxidant insults and serves a vital function in
maintaining cellular homeostasis through anti-oxida-
tive, anti-inflammatory, and anti-apoptotic actions (13,
14). In studies concerning the anti-apoptotic features
of HO-1 (15–19), different metalloporphyrins are often
used to either stimulate HO-1 expression or inhibit its
activity, in combination with various assay methods
such as the measurement of caspase-3-like activity.
Here we can report an important finding: the HO-1
inhibitors tin and zinc(II) protoporphyrin IX (SnPP,
ZnPP) and the strong HO-1 inducer cobalt(III) proto-
porphyrin IX (CoPP) inhibit caspase activity unrelated
to HO-1 expression and activity in vitro and in vivo. In
fact, by using recombinant caspase-3 and -8 and by
performing molecular modeling studies for caspase-3, a
direct inhibition of caspase activity by the porphyrins
could be demonstrated.
MATERIALS AND METHODS
Reagents
Cell culture medium (RPMI 1640) and penicillin/streptomy-
cine were from PAN (Aidenbach, Germany). FCS was from
PAA Laboratories (Co¨lbe, Germany) and human, recombi-
nant Fas ligand, cobalt(III), tin, and zinc(II) protoporphyrin
were from Alexis (Gru¨nberg, Germany). Substrates for
caspase-3 and -8, Ac-DEVD-AFC and Ac-IETD-AFC, were from
Biosource (Solingen, Germany). The human recombinant
caspases-3 and -8 as well as the anti-PARP monoclonal mouse
antibody were purchased from Calbiochem (Schwalbach,
Germany), the ECL Plus Western Blot Detection Reagent
from Amersham Biosciences (Freiburg, Germany), and Com-
plete from Roche (Mannheim, Germany). Anti-hsp32
(HO-1) antibody, peroxidase-conjugated anti-caspase-3
(CPP32) antibody, and anti-CD95 (Fas) antibody were from
BD/PharMingen (Heidelberg, Germany), and peroxidase-
conjugated goat anti-mouse antibody was from Cell Signaling
(Frankfurt/M, Germany). Protoporphyrin IX disodium salt
was from Frontier Scientific Porphyrin Products (Carnforth/
Lancashire, UK). All other materials were purchased from
either Sigma (Taufkirchen, Germany), Carl-Roth GmbH
(Karlsruhe, Germany) or Merck-Eurolab (Munich, Ger-
many).
Cell culture
Human leukemia Jurkat T cells (clone J16) were cultured
(37°C and 5% CO2) in RPMI 1640 supplemented with 10%
FCS, penicillin (100 U/mL)/streptomycin (100 ng/mL), and
0.1 M pyruvate. For experiments, cells of passage numbers 3
to 15 were used at a density of 0.6 to 0.7  106 cells/mL.
Animal model
BALB/c-mice (age: 6–8 wk; weight range: 18–22 g) were
obtained from the animal facilities of the Institute of Exper-
imental and Clinical Pharmacology and Toxicology of the
University of Erlangen-Nuremberg, Erlangen, Germany. All
mice received human care according to the guidelines of the
National Institute of Health as well as to the legal require-
ments in Germany. They were maintained under controlled
conditions (22°C, 55% humidity and 12 h day/night rhythm)
and fed a standard laboratory chow. Activating anti-CD95
antibody (Ab) was administered intravenously at 125 g/kg
in 200 L pyrogen-free saline. Animals were killed after 6 h
and livers were frozen in liquid nitrogen. Cobalt(III) proto-
porphyrin IX (CoPP, i.p., 10 mg/kg) and tin protoporphyrin
IX (SnPP, i.p., 25 mg/kg) were dissolved in sterile 0.2 M
NaOH and pH was adjusted to a neutral pH level. CoPP or
SnPP were administered 2 h after induction of liver injury by
anti-CD95 Ab.
Western blot analysis
Jurkat T cells were either left untreated or stimulated with Fas
ligand (FasL, 100 ng/mL) in the absence or presence of the
different porphyrins (CoPP, SnPP, ZnPP, 10 M each) or
treated with the porphyrins alone for the indicated times.
Western blot was performed as published previously (20).
Lysis buffer contained 150 mM NaCl, 50 mM Tris-HCl, 1%
Nonidet P40, 0.25% deoxycholate, and 0.1% SDS, supple-
mented with a protease inhibitor cocktail (Complete) and 1
mM PMSF. For electrophoresis gels were loaded with 10 g
protein/sample. ECL Plus Western Blot Detection Reagent
(Amersham Biosciences) and an AGFA Developer were used
for visualization of the bands.
Caspase activity measurement
Cells were treated with FasL (100 ng/mL) for the indicated
times in the presence or absence of the different porphyrins
(CoPP, SnPP, ZnPP, 10 M each) for the indicated times.
Caspase-3-like activity was measured in cell lysates and tissue
homogenates as described previously (21). Release of free
7-amino-4-trifluoromethyl coumarin (AFC) from the syn-
thetic substrate Ac-DEVD-AFC (50 M) at 37°C was deter-
mined by fluorescence measurement in a SpectraFluor Plus
plate reader (Tecan, Crailsheim, Germany) at an excitation
wavelength of 390 nm and an emission wavelength of 535 nm.
Activity of caspase-8 was determined similarly using Ac-IETD-
AFC as substrate.
Activity of recombinant caspase-3 and-8
Human recombinant caspase-3 and -8 were supplied as stock
solution in a buffer containing 50 mM HEPES (pH 7.4), 100
mM NaCl, 0.1% CHAPS, 1 mM EDTA, 10% glycerol and 10
mM dithiothreitol (DTT). Before each experiment, the stock
solutions were diluted to 2 U/L with buffer A (50 mM
HEPES pH 7.4, 100 mM NaCl, 0.1% CHAPS, 1 mM EDTA,
10% glycerol) plus 400 M DTT. Activity of the enzymes
(final concentration: 40 U/mL) was measured at 37°C in 100
L buffer A (without addition of DTT) following the gener-
ation of free AFC from the synthetic substrate Ac-DEVD-AFC
for caspase-3 or Ac-IETD-AFC for caspase-8 respectively (50
M each) with a SpectraFluor Plus plate reader. Metallopor-
phyrins were used in a concentration range between 0.001
and 100 M.
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Molecular modeling
Automated docking analysis was carried out by using
AutoDock 3.0 (22). The crystal structure of caspase-3 was
obtained from the Brookhaven Protein Databank (code:
1QX3). To identify potential ligand locations, a protoporphy-
rin molecule (without metal ligand) was docked in the active
site of the enzyme. Protoporphyrin was taken due to the fact
that standard force field methods cannot calculate physico-
chemical properties of metal ions adequately. The ligand was
kept flexible so that it could adjust to the positions of the
protein side chains. Fifty independent docking runs were
carried out. For each calculation, similar ligand geometries
were clustered and represented by the one with the most
favorable interaction energy. The obtained complexes were
energetically minimized by using a conjugate gradient algo-
rithm permitting the ligand side chain atoms to relax. Energy
minimizations were carried out by using the PRGEN program
(23). To validate the results obtained by the docking proce-
dure, a series of GRID calculations was performed. The
program predicts favorable interactions between a molecule
of known 3-dimensional structure (i.e., caspase-3) and differ-
ent probes representing characteristic chemical features of a
ligand molecule. Unlike the docking studies, the complete
structure of caspase-3 was investigated here, in order to search
for possible protoporphyrin binding sites in addition to the
known active site.
Statistical analysis
Unless stated otherwise at least three independent experi-
ments were performed in triplicates. Data are expressed as
mean  se. Values with P  0.05 were considered statistically
different compared with control cells (one-sample t test).
Statistical analysis was performed with Graph Pad Prism
(version 3.02).
RESULTS
Porphyrins inhibit FasL-induced caspase-3-like
activity in vitro
Inhibition of caspase-3-like activity by different metal-
loporphyrins was determined using Jurkat T-lympho-
cytes treated with FasL (100 ng/mL) for various times.
Enzyme activity is recorded as an increase in fluores-
cence due to cleavage of the caspase-3 substrate Ac-
DEVD-AFC. As shown in Fig. 1A, the HO-1 inducer
cobalt(III) protoporphyrin-IX (CoPP, 10 M) as well as
the HO-1 inhibitors tin and zinc(II) protoporphyrin-IX
(SnPP, ZnPP, 10 M each) were able to inhibit enzyme
activity induced by FasL.
The different metalloporphyrins, as well as FasL,
have been demonstrated to affect HO-1 expression in
different cell types including Jurkat cells (12, 24).
However, Western blot analysis assured that in our
experimental setting HO-1 was neither induced by FasL
nor by porphyrins (Fig. 1B). Therefore, the effect on
caspase activity by the metalloporphyrins seems to be
HO-1-independent.
Metalloporphyrins inhibit caspase-3-dependent
PARP cleavage
Poly-ADP ribose polymerase (PARP) is known to be a
prominent substrate of caspase-3 during apoptosis. In
fact, Western blot analysis of Jurkat T-lymphocytes
revealed a reduction of the 85 kDa cleavage product of
PARP in CoPP-treated cells compared with Jurkat cells
treated with FasL alone (Fig. 1C).
Figure 1. The influence of metalloporphyrins on caspase-3-
like activity, HO-1 protein expression, and PARP cleavage in
intact Jurkat T-lymphocytes. A) Cells were either left un-
treated (Co) or treated with Fas ligand (FasL, 100 ng/mL,
16 h). The HO-1 inducer cobalt(III) protoporphyrin-IX
(CoPP, 10 M) and the HO-1 inhibitors tin and zinc(II)
protoporphyrin-IX (SnPP, ZnPP, 10 M each) were added 30
min before the cells were lysed. Caspase-3-like activity was
determined. Bars represent means se of 3 independent
experiments performed in triplicates and values of untreated
cells were set as 1. ***P  0.001 represents significant
differences compared with Co. P  0.001 represents
significant differences compared with cells treated with FasL
alone. B) To detect HO-1 protein expression by Western blot,
cells were either left untreated (Co) or treated with FasL (100
ng/mL, 16 h) or with the different porphyrins (CoPP, SnPP,
ZnPP, 10 M each, 30 min). Human umbilical vein endothe-
lial cells (HUVEC) treated with CoPP (10 M, 30 min) served
as a positive control (P) for induction of HO-1 protein
expression. One representative blot of three is shown. C) To
detect PARP cleavage by Western blot, cells were either left
untreated (Co) or treated with FasL (100 ng/mL) alone or
together with CoPP (10 M) for 6 h. Experiments were
performed 3 times with consistent results and 1 representative
blot is shown.
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Porphyrin treatment inhibits caspase-3-like activity
in vivo
Mice were treated with activating anti-CD95-antibody
for 6 h resulting in high caspase-3 activity. CoPP and
SnPP were administered 2 h after anti-CD95-antibody
in order to make sure that no considerable HO-1
protein expression occurred yet (data not shown).
Measurement of caspase-3-like activity in liver homoge-
nates clearly showed that metalloporphyrins are able to
inhibit this enzyme in vivo (Fig. 2).
Porphyrins are direct caspase-3 inhibitors
To elucidate the mechanism of caspase inhibition,
porphyrins were added directly to lysates of FasL-
treated Jurkat cells containing activated caspases. Activ-
ities, as shown in Fig. 3, gave a first hint that the mode
of inhibition may occur in a direct manner. The three
metalloporphyrins showed an even stronger inhibitory
effect on caspase-3-like activity than in whole cells.
To further confirm a direct inhibition of caspase-3-
like activity by porphyrins, recombinant caspase-3 was
used. As can be seen in Fig. 4A, cobalt, tin, and zinc
protoporphyrin were able to inhibit the isolated en-
zyme. The IC50 values of the three metalloporphyrins
Figure 4. Metalloporphyrins and protoporphyrin sodium salt
influence the activity of recombinant caspase-3. CoPP
(0.001–10 M), SnPP (0.001–100 M), ZnPP (0.001–100 M
(A), or protoporphyrin-IX disodium salt (PP, 10 M) (C)
were added to recombinant caspases-3 (C-3) immediately
before measurement of caspase activity. In further experi-
ments, CoPP (10 M) was added to recombinant caspase-3
with increasing amounts of the caspase-3 substrate (B). Data
represent means  se of 3 independent experiments per-
formed in triplicates and activity of caspase-3 in the absence
of the porphyrins was taken as 100%. ***P 0.001 represents
significant differences compared with the respective C-3
group.
Figure 2. Porphyrins influence caspase-3-like activity in vivo.
Mice were treated with CoPP (10 mg/kg) or SnPP (25
mg/kg) 2 h after induction of caspase activity by activating
anti-CD95 Abs (anti-CD95 Ab, 10 mg/kg). Caspase-3-like
activity was measured at 6 h after challenge. SnPP was added
to liver homogenates of mice treated with anti-CD95 Ab
immediately before the measurement of caspase activity serv-
ing as a positive control (P). Bars represent means  se of 4
mice and values of anti-CD95 Ab-treated mice were set as
100%. **P  0.01, *P  0.05 represent significant differences
compared with anti-CD95 Ab-treated animals.
Figure 3. The effect of metalloporphyrins on caspase-3-like
activity in cell lysates of Jurkat T-lymphocytes. Cells were
either left untreated (Co) or treated with FasL (100 ng/mL,
16 h). CoPP, SnPP, and ZnPP (10 M each) were added to
the cell lysates immediately before the measurement of
caspase activity. Bars represent means  se of 3 indepen-
dent experiments performed in triplicates and values of
FasL-treated cells were set as 100%. ***P 0.001 represents
significant differences compared with Co. P  0.001
represents significant differences compared with cells
treated with FasL.
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demonstrate that the inhibitory potency of CoPP (IC50
10 nM) clearly exceeds that of the two other porphy-
rins (IC50 2.5 M).
Using increasing amounts of the caspase-3-substrate
revealed that the inhibitory effect of the porphyrins is
not reversible at substrate concentrations of up to 1
mM, as shown in Fig. 4B.
The fact that protoporphyrin IX lacking the metal
moiety, was able to inhibit caspase-3 activity (Fig. 4C)
points to the protoporphyrin ring as responsible struc-
tural element for the caspase-3 inhibition. Molecular
modeling data confirmed this assumption.
Caspase-3-processing is inhibited by protoporphyrins
Active caspase-3 is cleaved from its inactive zymogen
procaspase-3 by initiator caspases such as caspase-8. As
shown in Fig. 5, treatment with FasL leads to a decrease
of the uncleaved procaspase-3. In the presence of CoPP
the processing of procaspase-3 is blocked. The same
effect could be seen for SnPP (data not shown). This
suggests that porphyrins also interfere with caspases
upstream of caspase-3.
Metalloporphyrins inhibit caspase-8 activity
To clarify, if the inhibitory effect of the porphyrins is
specific for caspase-3 or if other caspases are equally
affected, we looked at the activity of caspase-8, as a
representative of the initiator caspases upstream of the
executive caspase-3. Application of porphyrins to whole
cells (Fig. 6A), cell lysates of FasL-activated Jurkat cells
(Fig. 6B) or directly to recombinant caspase-8 (Fig. 6C)
showed similar inhibitory action on caspase-8 activity as
on caspase-3 activity. Caspase-8 was inhibited by the
porphyrins in the in vivo model (Fig. 6D).
Molecular modeling studies
Molecular modeling studies confirmed the biochemical
data. The protoporphyrin fits well into the active site of
caspase-3, as can be seen from the molecular superpo-
sition of the binding conformations extracted from the
AutoDock results (Fig. 7A).
In Fig. 7B, the energetically most favorable interac-
tion complex can be viewed in detail: one carboxylate
group of the protoporphyrin forms a bidentate salt
bridge to the guanidinium group of Arg-341. Moreover,
one of the carboxylate oxygens forms a hydrogen bond
with the backbone –NH of Ser-180. The second carbox-
ylate group acts as a hydrogen bond acceptor for the
backbone NH of Arg-341 and for the –OH of Tyr-338.
The –OH group of Ser-343 points in the direction of
the N/NH atoms of the protoporphyrin in a way that
either hydrogen bonds or interactions with a central
metal cation can occur. The protoporphyrin carbon
Figure 5. Procaspase-3-processing is affected by protoporphy-
rins. Jurkat T-lymphocytes were either left untreated (Co) or
treated with FasL (100 ng/mL) in the presence or absence of
CoPP (10 M) for the indicated times. Cellular levels of
uncleaved procaspase-3 were examined by Western blot. The
experiment was performed 3 times and 1 representative blot
is shown.
Figure 6. Effect of metalloporphyrins on caspase-8-
like activity. Cells were either left untreated (Co) or
treated with FasL (100 ng/mL, 5 h). CoPP, SnPP or
ZnPP (10M each) were added either 30 min before
the cells were lysed (A) or immediately before mea-
surement of caspase-8-like activity (B). The metallo-
porphyrins (10 M each) were added to recombi-
nant caspases-8 (C-8) immediately before the
measurement of caspase activity (C). Bars represent
means  se of 2 independent experiments per-
formed in triplicates and values of untreated cells
were set as 1. ***P  0.001 represents significant
differences compared with Co. P 0.001 repre-
sents significant differences compared with cells
treated with FasL alone. Mice were treated with CoPP
(10 mg/kg) or SnPP (25 mg/kg) 2 h after induction
of caspase activity by activating anti-CD95 Abs (anti-
CD95 Ab, 10 mg/kg) (D). Activity of caspase-8 was
detected at 6 h after challenge. SnPP was added to
liver homogenates of mice treated with anti-CD95 Ab
immediately before the measurement of caspase
activity serving as a positive control (P). Bars repre-
sent means  se of 4 mice and values of anti-CD95
Ab-treated mice were set as 100%. ***P 0.001, **P
 0.01, *P  0.05 represent significant differences
compared with anti-CD95 Ab-treated animals.
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skeleton makes some hydrophobic contacts with Thr-
177, Trp-340, and Phe-381B.
The program “GRID” was used to test the complete
protein for areas that offered energetically favorable
interactions with a ligand molecule. Since the proto-
porphyrin molecule exhibits mainly carbons and car-
boxylate groups, which may act as binding partners for
a protein, we selected a hydrophobic probe and a CO–
probe as representatives. The calculations suggest that
the most favored region of interactions for the probes is
located in the active site of the enzyme, which is in
agreement with our docking procedure. However, from
the GRID results one further potential binding region
was detected. To evaluate its suitability to act as a
specific binding site for the protoporphyrin, subse-
quent AutoDock investigations were performed (data
not shown). No energetically favorable binding mode
was detected by AutoDock since the protoporphyrin
molecule is too bulky to fit well into this pocket. As
mentioned above, metal ion properties and influences
cannot be estimated reliably with force field methods.
To investigate the differences seen in the various met-
alloporphyrins on caspase-3 activity, extensive quantum
chemical computations have to be performed.
DISCUSSION
In the present study, we show that different metallopor-
phyrins can inactivate caspases in vitro as well as in vivo.
This inactivation could be seen when adding the por-
phyrins to cells or tissue where the caspases had been
activated during apoptosis, to cell lysates containing the
activated enzymes, and to recombinant caspase-3 and
-8. This strongly suggests that the observed inhibitory
effect is a direct one.
Most important, the data indicate that metallopor-
phyrins seem to have additional effects to their HO-
dependent actions. It has been shown that different
metalloporphyrins have a substantial effect on other
heme-depending enzymes, such as guanylate cylcase
and nitric oxide synthase (25–27). However, the
caspases do not contain heme. Thus, the outcome of
this study may show a novel mode of action for the
metalloporphyrins and introduces them as a new class
of caspase inhibitors.
The metalloporphyrin cobalt(III) protoporphyrin IX
is often used as a strong HO-1 inducer in experimental
settings concerning the functions of HO-1. In fact,
CoPP acts as inhibitor of HO-1 activity, like the other
metalloporphyrins, as it cannot be converted to the
heme degradation products but is able to bind to the
catalytic site of the enzyme. On the other hand, CoPP is
able to induce the HO-1 expression by a mechanism
fundamentally different from that of sodium arsenite
and other stress inducers, possibly via a newly identified
regulatory region of the HO-1 gene named metallopor-
phyrin-responsive element (MPRE) (10). Those differ-
ent effects on HO-1 activity and expression by CoPP
result in total in an increased HO-1 activity.
Based on our findings, attention should be paid to
the usage of porphyrins as HO-1 modulators in exper-
imental settings, which include the measurement of
caspase-3-like activity. As shown by the presented data,
direct effects of porphyrins on caspases could occur
time dependently, independent of HO-1 expression.
Certainly, our data do not argue against several studies
using other HO-1 inducers than CoPP, such as sodium
arsenite (28), tetracycline-regulated expression systems
(29), adenoviral transfer (15), or doxorubicin (30),
and reporting cytoprotective features of HO-1.
In contrast to CoPP, SnPP and ZnPP are generally
viewed as being only weak inducers of HO-1 expression
(11). However, there are contradictory results that
claim ZnPP is the most potent inducer of HO-1 expres-
sion (31). Nevertheless, it has been proved that tin- and
zinc-containing porphyrins decrease HO-1 activity, jus-
tifying their usage as potent HO-1 inhibitors. Based on
our findings, using SnPP and ZnPP as HO-1 inhibitors
in order to prove anti-apoptotic functions of HO-1
could also lead to contradictory results depending on
the time frame.
Metalloporphyrins as inhibitors of caspase-3 and -8
raise the question of the physiological function of these
compounds. A possible in vivo relevance may be dis-
cussed using zinc protoporphyrin as an example. Re-
Figure 7. Auto-Dock results. Caspase-3 together with 10
putative binding conformations of protoporphyrin (A). Rep-
resentation of the energetically most favorable caspase-3/
protoporphyrin complex showing the major protein-ligand
interactions (B).
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search concerning ZnPP as a naturally occurring me-
tabolite of heme biosynthesis has dramatically
increased in the past decade. So far, proposed physio-
logical functions are the control of heme catabolism
until bilirubin conjugation becomes activated in neo-
nates and a possible modulation of CO production in
brain metabolism (32). In addition, the therapeutic
potential of ZnPP and other metalloporphyrins has
attracted interest in the treatment of hyperbiliru-
binemia (33, 34). As yet, all of these suggested func-
tions have been connected to the inhibitory effect of
ZnPP on the heme oxygenase system. Our data intro-
duce a direct inhibitory effect on caspase activity as an
additional mechanism of action of ZnPP. This knowl-
edge may provide a better understanding of the role of
this metabolite in physiology as well as in pathophysi-
ology.
Our work identifies metalloporphyrins as a novel
class of irreversible caspase inhibitors. So far, known
inhibitors are members of the family of inhibitors of
apoptosis protein (IAP) and the two virus-derived pro-
teins cowpox serpin CrmA and p35 from baculovirus
(35). Besides these naturally occurring compounds,
well established and widely used caspase inhibitors have
been generated by synthetically coupling caspase-spe-
cific peptide-sequences to certain aldehyde (CHO),
chloromethylketone (CMK), fluoroacyloxymethylke-
tone (FAOM), or fluoromethylketone (FMK) com-
pounds (36).
Several X-ray crystal structures reveal how specific
peptidic and non-peptidic inhibitors bind to caspase-3
(37–40). The ligands occupy the active site of the
caspase in the S1-S4 regions. The interactions between
the ligands and the protein mainly result from hydro-
phobic contacts and hydrogen bonds. A free carboxyl
acid seems to play an important role in the ligand
structure since it is critical for the binding of the
inhibitors to the caspase enzyme. Our investigations
demonstrate that the protoporphyrin can occupy the
active site of caspase-3 energetically favorable and in a
binding mode similar to that of known inhibitors. This
postulated binding mode is consistent with crystal data
of caspase-3, in which the inhibitors occupy similar
parts of the active site. The very potent peptidic inhib-
itor XIAP-BIR2 exhibits an Asp-148 residue that is
essential for the inhibiting effect (mutations of Asp-148
lead to a complete loss of inhibitory activity). Asp-148
forms hydrogen bonds via its backbone and its side
chain atoms to Arg-341 and Ser-343. The protoporphy-
rin seems to meet the structural requirements for
caspase inhibitors well since it is able to form (among
hydrophobic contacts) the important interactions be-
tween its free carboxylic acids and the corresponding
amino acids in the catalytic center of the enzyme.
To clarify the possible molecular mechanism of inhi-
bition, we examined which part of the metalloporphy-
rin complex is responsible for the inhibitory effect on
caspase-3-like activity. In fact, we saw a similar effect by
using protoporphyrin IX disodium salt on the isolated
caspase-3. Thus, it may be that the inhibition of the
caspase activity by the metalloporphyrins is mainly
accountable to the porphyrin ring. However, CoPP is
the most efficient inhibitor of the three metalloporphy-
rins. It has been shown that heavy metals like zinc at
micromolar concentrations are able to influence activ-
ity of the isolated caspase-3 (41–43), possibly by coor-
dinating with one or two amino acids of the active site
of the enzyme. However, considering the complex
stabilities of typical metalloporphyrins that allow free
metal to occur in the attomolar (1018 M) range (44),
it is most unlikely that enough free metal is available to
account for the observed effect. Detailed molecular
modeling studies are under way to investigate effects on
other caspases as well as the molecular basis for the
differences seen in the various metalloporphyrins.
In summary, the finding that metalloporphyrins di-
rectly inhibit caspase activity points to a novel class of
caspase inhibitors, but also requests their careful use as
modulators of the HO system (Fig. 8).
The excellent technical support of Cornelia Niemann and
Johanna Sto¨ckl is gratefully acknowledged. This work was
supported by the Deutsche Forschungsgemeinschaft (DFG
FOR440/1 TP 2; Vo 376/10-1). A.K.K. is supported by the
Alexander von Humboldt foundation.
REFERENCES
1. Leist, M., and Nicotera, P. (1997) The shape of cell death.
Biochem. Biophys. Res. Commun. 236, 1–9
2. Denault, J. B., and Salvesen, G. S. (2002) Caspases: keys in the
ignition of cell death. Chem. Rev. 102, 4489–4500
3. Nicotera, P., and Melino, G. (2004) Regulation of the apoptosis-
necrosis switch. Oncogene 23, 2757–2765
4. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P.,
Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M.,
and Lazebnik, Y. A. (1995) Identification and inhibition of the
ICE/CED-3 protease necessary for mammalian apoptosis. Nature
(London) 376, 37–43
Figure 8. Schematic model of caspase inhibition by the
porphyrins. Besides the known mechanism of metalloporphy-
rins to interfere with apoptosis via HO-1 modulation, porphy-
rins can directly inhibit caspases after activation by proapo-
ptotic stimuli.
1278 Vol. 19 August 2005 BLUMENTHAL ET AL.The FASEB Journal
5. Gurtu, V., Kain, S. R., and Zhang, G. (1997) Fluorometric and
colorimetric detection of caspase activity associated with apopto-
sis. Anal. Biochem. 251, 98–102
6. Tenhunen, R., Marver, H. S., and Schmid, R. (1968) The
enzymatic conversion of heme to bilirubin by microsomal heme
oxygenase. Proc. Natl. Acad. Sci. USA 61, 748–755
7. Maines, M. D. (1997) The heme oxygenase system: a regulator
of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37,
517–554
8. Smith, K. M., and Falk, J. E. (1975) Porphyrins and Metalloporphy-
rins, 2nd Ed., Elsevier Scientific Publ. Co., Amsterdam
9. Maines, M. D. (1981) Zinc. protoporphyrin is a selective inhib-
itor of heme oxygenase activity in the neonatal rat. Biochim.
Biophys. Acta 673, 339–350
10. Shan, Y., Pepe, J., Lambrecht, R. W., and Bonkovsky, H. L.
(2002) Mapping of the chick heme oxygenase-1 proximal
promoter for responsiveness to metalloporphyrins. Arch. Bio-
chem. Biophys. 399, 159–166
11. Shan, Y., Pepe, J., Lu, T. H., Elbirt, K. K., Lambrecht, R. W., and
Bonkovsky, H. L. (2000) Induction of the heme oxygenase-1
gene by metalloporphyrins. Arch. Biochem. Biophys. 380, 219–227
12. Sardana, M. K., and Kappas, A. (1987) Dual control mechanism
for heme oxygenase: tin(IV)-protoporphyrin potently inhibits
enzyme activity while markedly increasing content of enzyme
protein in liver. Proc. Natl. Acad. Sci. USA 84, 2464–2468
13. Ryter, S. W., Otterbein, L. E., Morse, D., and Choi, A. M. (2002)
Heme oxygenase/carbon monoxide signaling pathways: regula-
tion and functional significance. Mol. Cell. Biochem. 234/235,
249–263
14. Kampfer, H., Kolb, N., Manderscheid, M., Wetzler, C.,
Pfeilschifter, J., and Frank, S. (2001) Macrophage-derived
heme-oxygenase-1: expression, regulation, and possible func-
tions in skin repair. Mol. Med. 7, 488–498
15. Sass, G., Soares, M. C., Yamashita, K., Seyfried, S., Zimmermann,
W. H., Eschenhagen, T., Kaczmarek, E., Ritter, T., Volk, H. D.,
and Tiegs, G. (2003) Heme oxygenase-1 and its reaction prod-
uct, carbon monoxide, prevent inflammation-related apoptotic
liver damage in mice. Hepatology 38, 909–918
16. Dorman, R. B., Bajt, M. L., Farhood, A., Mayes, J., and Jaeschke,
H. (2004) Heme oxygenase-1 induction in hepatocytes and
non-parenchymal cells protects against liver injury during en-
dotoxemia. Comp. Hepatol. 3, Suppl. 1, S42
17. Zhang, X., Shan, P., Jiang, D., Noble, P. W., Abraham, N. G.,
Kappas, A., and Lee, P. J. (2004) Small interfering RNA target-
ing heme oxygenase-1 enhances ischemia-reperfusion-induced
lung apoptosis. J. Biol. Chem. 279, 10677–10684
18. Liu, Z. M., Chen, G. G., Ng, E. K., Leung, W. K., Sung, J. J., and
Chung, S. C. (2004) Upregulation of heme oxygenase-1 and p21
confers resistance to apoptosis in human gastric cancer cells.
Oncogene 23, 503–513
19. Akamatsu, Y., Haga, M., Tyagi, S., Yamashita, K., Graca-Souza,
A. V., Ollinger, R., Czismadia, E., May, G. A., Ifedigbo, E.,
Otterbein, L. E., et al. (2004) Heme oxygenase-1-derived carbon
monoxide protects hearts from transplant associated ischemia
reperfusion injury. FASEB J. 18, 771–772
20. Kiemer, A. K., and Vollmar, A. M. (1998) Autocrine regulation
of inducible nitric-oxide synthase in macrophages by atrial
natriuretic peptide. J. Biol. Chem. 273, 13444–13451
21. Dirsch, V. M., Muller, I. M., Eichhorst, S. T., Pettit, G. R.,
Kamano, Y., Inoue, M., Xu, J. P., Ichihara, Y., Wanner, G., and
Vollmar, A. M. (2003) Cephalostatin 1 selectively triggers the
release of Smac/DIABLO and subsequent apoptosis that is
characterized by an increased density of the mitochondrial
matrix. Cancer Res. 63, 8869–8876
22. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart,
W. E., Belew, R. K., and Olson, A. J. (1998) automated docking
using a lamarckian genetic algorithm and empirical binding
free energy function. J. Comput. Chem. 19, 1639
23. Zbinden, P., Dobler, M., Folkers, G., and Vedani, A. (1998)
PrGen: Pseudoreceptor modeling using receptor-mediated li-
gand alignment and pharmacophore equilibration. Quant.
Struct. Act. Relat. 17, 122
24. Pae, H. O., Choi, B. M., Oh, G. S., Lee, M. S., Ryu, D. G., Rhew,
H. Y., Kim, Y. M., and Chung, H. T. (2004) Roles of heme
oxygenase-1 in the antiproliferative and antiapoptotic effects of
nitric oxide on Jurkat T cells. Mol. Pharmacol. 66, 122–128
25. Luo, D., and Vincent, S. R. (1994) Metalloporphyrins inhibit
nitric oxide-dependent cGMP formation in vivo. Eur. J. Pharma-
col. 267, 263–267
26. Serfass, L., and Burstyn, J. N. (1998) Effect of heme oxygenase
inhibitors on soluble guanylyl cyclase activity. Arch. Biochem.
Biophys. 359, 8–16
27. Jozkowicz, A., and Dulak, J. (2003) Effects of protoporphyrins
on production of nitric oxide and expression of vascular endo-
thelial growth factor in vascular smooth muscle cells and
macrophages. Acta Biochim. Pol. 50, 69–79
28. Fauconneau, B., Petegnief, V., Sanfeliu, C., Piriou, A., and
Planas, A. M. (2002) Induction of heat shock proteins (HSPs) by
sodium arsenite in cultured astrocytes and reduction of hydro-
gen peroxide-induced cell death. J. Neurochem. 83, 1338–1348
29. Petrache, I., Otterbein, L. E., Alam, J., Wiegand, G. W., and
Choi, A. M. (2000) Heme oxygenase-1 inhibits TNF-alpha-
induced apoptosis in cultured fibroblasts. Am. J. Physiol. 278,
L312–L319
30. Ito, K., Ozasa, H., Sanada, K., and Horikawa, S. (2000) Doxo-
rubicin preconditioning: a protection against rat hepatic isch-
emia-reperfusion injury. Hepatology 31, 416–419
31. Yang, G., Nguyen, X., Ou, J., Rekulapelli, P., Stevenson, D. K.,
and Dennery, P. A. (2001) Unique effects of zinc protoporphy-
rin on HO-1 induction and apoptosis. Blood 97, 1306–1313
32. Labbe, R. F., Vreman, H. J., and Stevenson, D. K. (1999) Zinc
protoporphyrin: A metabolite with a mission. Clin. Chem. 45,
2060–2072
33. Stevenson, D. K., Rodgers, P. A., and Vreman, H. J. (1989) The
use of metalloporphyrins for the chemoprevention of neonatal
jaundice. Am. J. Dis. Child. 143, 353–356
34. Maines, M. D., and Trakshel, G. M. (1992) Differential regula-
tion of heme oxygenase isozymes by Sn- and Zn-protoporphy-
rins: possible relevance to suppression of hyperbilirubinemia.
Biochim. Biophys. Acta 1131, 166–174
35. Stennicke, H. R., Ryan, C. A., and Salvesen, G. S. (2002)
Reprieval from execution: the molecular basis of caspase inhi-
bition. Trends Biochem. Sci. 27, 94–101
36. Cohen, G. M. (1997) Caspases: the executioners of apoptosis.
Biochem. J. 326, 1–16
37. Rotonda, J., Nicholson, D. W., Fazil, K. M., Gallant, M., Gareau,
Y., Labelle, M., Peterson, E. P., Rasper, D. M., Ruel, R., Vaillan-
court, J. P., et al. (1996) The three-dimensional structure of
apopain/CPP32, a key mediator of apoptosis. Nat. Struct. Biol. 3,
619–625
38. Lee, D., Long, S. A., Adams, J. L., Chan, G., Vaidya, K. S.,
Francis, T. A., Kikly, K., Winkler, J. D., Sung, C. M., Debouck, C.,
et al. (2000) Potent and selective nonpeptide inhibitors of
caspases 3 and 7 inhibit apoptosis and maintain cell function-
ality. J. Biol. Chem. 275, 16007–16014
39. Riedl, S. J., Renatus, M., Schwarzenbacher, R., Zhou, Q., Sun, C.,
Fesik, S. W., Liddington, R. C., and Salvesen, G. S. (2001)
Structural basis for the inhibition of caspase-3 by XIAP. Cell 104,
791–800
40. Erlanson, D. A., Lam, J. W., Wiesmann, C., Luong, T. N.,
Simmons, R. L., DeLano, W. L., Choong, I. C., Burdett, M. T.,
Flanagan, W. M., Lee, D., et al. (2003) In situ assembly of
enzyme inhibitors using extended tethering. Nat. Biotechnol. 21,
308–314
41. Perry, D. K., Smyth, M. J., Stennicke, H. R., Salvesen, G. S.,
Duriez, P., Poirier, G. G., and Hannun, Y. A. (1997) Zinc is a
potent inhibitor of the apoptotic protease, caspase-3. A novel
target for zinc in the inhibition of apoptosis. J. Biol. Chem. 272,
18530–18533
42. Stennicke, H. R., and Salvesen, G. S. (1997) Biochemical
characteristics of caspases-3, -6, -7, and -8. J. Biol. Chem. 272,
25719–25723
43. Kown, M. H., Van der, Steenhoven, T., Blankenberg, F. G.,
Hoyt, G., Berry, G. J., Tait, J. F., Strauss, H. W., and Robbins,
R. C. (2000) Zinc-mediated reduction of apoptosis in cardiac
allografts. Circulation 102, III228–III232
44. Bonnett, R. (2003) Comprehensive Coordination Chemistry II, Vol. 9:
Metal Complexes for Photodynamic Therapy, 2nd Ed., Elsevier
Scientific Publ. Co., Amsterdam
Received for publication October 14, 2004.
Accepted for publication November 1, 2004.
1279CASPASE INHIBITION BY PORPHYRINS
